Abiopharma

Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer

BioNTech veröffentlicht am 3. November 2025 Ergebnisse für das dritte Quartal 2025 und informiert über operativen Fortschritt

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

MLTX INVESTOR NOTICE: MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

DocGo to Announce Third Quarter 2025 Results on Monday, November 10, 2025

BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers

Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System

BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market

TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohns disease at two years

Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis